Aatru Medical has signed an agreement with Salus Biomedical for the distribution of its Negative Pressure Surgical Incision Management System (NPSIMS) product in Latin America.

The company is finalising market introduction plans for NPSIMS, which has received US Food and Drug Administration (FDA) 510(k) clearance.

Initially, Salus Biomedical will distribute the product in Latin American markets, with US and other worldwide markets to follow.

Utilising a safe solid-state chemical reaction, NPSIMS creates and applies negative pressure in the treatment range to close incision sites for up to seven days.

It has a unique mode of action, with no moving parts or electromechanical components, and delivers similar clinical performance to other Negative Pressure Wound Therapy (NPWT) devices that are currently available.

Aatru Medical COO Tom Lash said: “Market analysis and voice-of-customer feedback identified that users value the role of NPWT products in helping manage the risk of surgical site infections (SSI), although product complexity and the high cost of currently-available NPWT products is restricting use to mainly higher-risk incisions only.

“The NPSIMS product provides similar clinical performance while providing significant cost improvement over existing devices, creating a more scalable standard of care to treat the vast majority of low-exudate surgical incisions.”

The single-use disposable device needs no electromechanical pump, battery or canister. It also delivers advantages in ease of use, patient quality of life and price.

Salus Biomedical managing director Israel Vierma said: “We are proud to be at the forefront of incision care with this simple, most innovative and useful product.

“Aatru Medical is breaking new ground on ease-of-use for the clinicians and in helping us address a growing need in Latin America.”